arrow
A

Alan Ashworth

University of California San Francisco
H指数:121
被引数:6.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of a random background to understand ligand optimization

开发随机背景以理解配体优化

Nature
IF48.5
2026-09-160
OAAI
Publisher Correction: Targeting cancer-specific mutations with RNA-triggered chromatin shredding

Publisher Correction: 靶向癌症特异性突变,利用RNA触发的染色质切碎

Nature
IF48.5
2026-08-140
PRE
Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding

利用RNA触发的染色质降解靶向癌症特异性突变

Nature
IF48.5
2026-06-080
PRE
Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo
2025-12-010
PRE
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2

Mac1 ADP-核糖基水解酶是SARS-CoV-2的 therapeutic target。

2025-11-191
OA
Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models

协调的蛋白质模块在人类卵巢癌模型中定义了卡铂诱导的DNA损伤反应的单细胞分辨率。

2025-08-220
OAAI
Correction: Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England

更正:评估新抗菌药物的价值:评估铁载体头孢菌素(Cefiderocol)和头孢他啶-阿维巴坦(Ceftazidime-Avibactam)以供英格兰国家医疗服务体系(NHS)进行脱钩支付决策

2025-06-020
OAAI
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2024-05-101
PRE
Generation and comparative analysis of an Itga8-CreERT2 mouse with preferential activity in vascular smooth muscle cells (vol 1, pg 1084, 2022)
2023-06-090
OA